SERPASIL-APRESOLINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SERPASIL-APRESOLINE (SERPASIL-APRESOLINE).
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases cGMP via NO).
| Metabolism | Reserpine: hydrolyzed in gut, metabolites excreted in urine. Hydralazine: N-acetylation via NAT2. |
| Excretion | Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance. |
| Half-life | Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment. |
| Protein binding | Reserpine: ~96% (bound to albumin and α1-acid glycoprotein). Hydralazine: 85-90% (primarily albumin; also binds to α1-acid glycoprotein and lipoproteins). |
| Volume of Distribution | Reserpine: ~8-10 L/kg (extensive tissue binding, especially adipose and brain). Hydralazine: 1.5-8 L/kg (increases with hypertension; reflects high tissue distribution). |
| Bioavailability | Reserpine: 5-30% oral (extensive first-pass metabolism; variable). Hydralazine: 30-50% oral (slow acetylators have higher bioavailability due to reduced first-pass acetylation; rapid acetylators 10-30%). |
| Onset of Action | Reserpine: 3-6 hours oral, up to 1 week for full effect. Hydralazine: 20-30 minutes oral; 5-20 minutes intramuscular; immediate intravenous (5-15 min for peak effect). |
| Duration of Action | Reserpine: 6-24 hours single dose; cumulative effect with repeated dosing; persistent autonomic effects due to irreversible vesicular monoamine transporter binding. Hydralazine: 2-6 hours oral; 2-4 hours parenteral; hypotensive effect may last up to 12 hours in slow acetylators. |
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR <30 mL/min: Use with caution; reduce hydralazine component by 50%. GFR 30-50 mL/min: No adjustment needed for hydralazine; reserpine use contraindicated if severe renal impairment. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce hydralazine dose by 50%. Child-Pugh C: Contraindicated due to risk of encephalopathy from reserpine and hepatotoxicity. |
| Pediatric use | Weight-based: 0.01 mg/kg reserpine and 2.5 mg/kg hydralazine per day orally, divided into 1-2 doses. Maximum: reserpine 0.25 mg/day, hydralazine 50 mg/day. |
| Geriatric use | Start at half the adult dose (1 tablet every other day) due to increased sensitivity to hypotension and CNS depression. Monitor for orthostatic hypotension and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SERPASIL-APRESOLINE (SERPASIL-APRESOLINE).
| Breastfeeding | Reserpine and hydralazine are excreted in breast milk. M/P ratio not well established. Reserpine may cause adverse effects in infants (diarrhea, nasal congestion). Hydralazine is considered compatible with caution. Avoid or use alternative antihypertensives with more safety data. |
| Teratogenic Risk | First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may cause neonatal hypotension, bradycardia, and hypothermia. Reserpine may increase risk of neonatal respiratory depression and nasal congestion. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to reserpine or hydralazine","Active peptic ulcer","Ulcerative colitis","Depression, especially with suicidal tendencies","Coronary artery disease (hydralazine may cause tachycardia)"]
| Precautions | ["Reserpine may cause depression, peptic ulcer, or arrhythmias.","Hydralazine may cause drug-induced lupus, peripheral neuritis, or orthostatic hypotension.","Monitor for hypotension and renal impairment."] |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure, heart rate, electrolyte levels, liver function, renal function, and signs of hypotension or fluid retention. Fetal: Serial ultrasound for growth, amniotic fluid volume, and heart rate assessment; nonstress test or biophysical profile in third trimester. |
| Fertility Effects | Reserpine may impair female fertility by altering pituitary-gonadal axis and prolactin levels; hydralazine has no known significant effect on fertility. |